Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Pfizer's rheumatoid arthritis drug shows benefit in COVID-19 pneumonia

06/16/2021 | 06:11pm EDT

June 16 (Reuters) - Pfizer Inc said on Wednesday its oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study's main goal.

Results of the study, which tested the drug in 289 hospitalized adult patients with the respiratory illness caused by the coronavirus, were published in the New England Journal of Medicine.

Pfizer said the incidence of death or respiratory failure was 18.1% for patients treated with the drug compared to 29% for placebo. Serious adverse events occurred in 20 patients treated with the drug compared to 17 patients on placebo.

Xeljanz, which belongs to a class of drugs called JAK inhibitors and also treats the autoimmune disease ulcerative colitis, has not been approved or authorized for use in any country for the treatment of COVID-19.

Pfizer and German partner BioNTech SE's vaccine is one of the three vaccines currently approved for emergency use in the United States.

(Reporting by Amruta Khandekar; Editing by Arun Koyyur)


ę Reuters 2021
Latest news "Economy & Forex"
12:59pU.S. senators urge barring Huawei, ZTE from $1.9 trillion gov't funding measure
RE
12:34pEfficacy Of Pfizer/Biontech COVID Vaccine Slips To 84% After Six Months, Data Show- Stat News
RE
12:34pEfficacy of pfizer/biontech covid vaccine slips to 84% after six months, data show- stat news
RE
12:33pEfficacy of pfizer/biontech covid vaccine slips to 84% after six months, data show- stat news
RE
12:31pTravel stocks lead UK mid-caps to all-time highs
RE
12:29pGoogle lifts Nasdaq as focus turns to Fed
RE
12:25pDuolingo valued at $6.5 bln as shares soar in debut
RE
12:21pSouth Africa's rand weakens as markets wait for Fed, stocks gain
RE
12:21pSterling surge in unusually high volumes stumps traders
RE
12:19pMcDonald's sales surge with help from BTS
RE
Latest news "Economy & Forex"